Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls. Brooke’s mother also had 28 surgeries related to her desmoid tumors and multiple ...

Panelists discuss the questions below in this video. What is the epidemiology and prognosis of desmoid tumor? Where on the body are desmoid tumors usually found? Can you please describe the ...

Varegacestat reduced the risk of disease progression or death by 84% compared with placebo in patients with progressing desmoid tumors. Topline data were announced from a phase 3 trial evaluating ...

Panelists discuss the questions below in this video. What is the pathophysiology of desmoid tumors and how does this differ from other soft tissue cancers?What is in your differential diagnosis when ...

(RTTNews) - Immunome, Inc. (IMNM) is scheduled to report topline Phase 3 results of its lead drug candidate, Varegacestat, in desmoid tumors, dubbed RINGSIDE trial, today. Desmoid tumors are rare, ...

In a continuation of its awareness and education efforts around desmoid tumors, SpringWorks Therapeutics has partnered with celebrity jewelry designer and patient advocate Jennifer Fisher. Just over ...

(RTTNews) - Immunome, Inc. (IMNM) Monday reported positive data from its pivotal Phase-3 RINGSIDE trial, in patients with desmoid tumors, with Varegacestat improving progression-free survival and ...

The US Food and Drug Administration approved nirogacestat (Ogsiveo, SpringWorks Therapeutics, Inc) to treat progressive, unresectable, recurrent, or refractory desmoid tumors in adults. Nirogacestat, ...

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial In the phase III ...

LEXINGTON, Ky. (LEX 18) — Diagnosed with a rare condition at age 18, Mackenzie Wilmoth has recovered, and she's leading the efforts to help those dealing with Pediatric Cancer. Wilmoth was in a ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global ...